News – Page 27 – Endpoints News

Small biotech joins list of health companies taking a trip to Trump's Mar-a-Lago

2 months ago

J&J touts new survival data pitting lung cancer combo against AstraZeneca's rival

2 months ago

Wave strengthens case for accelerated approval, with more positive Duchenne data

2 months ago

ElevateBio trims workforce by 17%

2 months ago

Humacyte to raise $50M; Acrivon to focus on prexasertib in endometrial cancer

2 months ago

The Endpoints Slack interview: Duke’s Pranam Chatterjee unpacks AI bio’s pretty picture fallacy

2 months ago

Epicrispr raises $68M, will start clinical trial of epigenetic editing for FSHD

2 months ago

Trump tariffs would increase costs for almost every biopharma company, survey claims

2 months ago

Senate confirms Makary as FDA chief with agency cuts, return-to-office in force

2 months ago

Covid contrarian Bhattacharya is confirmed as NIH chief, taking over at a fraught moment for federal research

2 months ago

Lyndra Therapeutics to wind down amid funding hurdles for long-acting drug technology

2 months ago

Eisai cuts Leqembi 2027 sales forecast by half but expects 'continued growth'

2 months ago

Senate committee backs Dr. Oz's nomination to lead CMS

2 months ago

Revvity secures $37.8M contract to help screen UK newborns for rare diseases

2 months ago

DOGE pulls three FDA lease closures from 'Wall of Receipts,' including St. Louis quality lab

2 months ago

Illumina adds activist investor to board, taps former FDA head as chair

2 months ago

Calculating healthcare's real costs

2 months ago

Axsome reports Phase 3 win for Sunosi in adults with ADHD, with a high-dose caveat

2 months ago

GSK scores FDA approval for antibiotic to treat uncomplicated UTIs

2 months ago

Exclusive: mRNA startup Turn Biotechnologies acquires Vesigen’s microvesicle delivery tech

2 months ago

WuXi Biologics’ licensing deals help offset Biosecure threat in the US

2 months ago

Kezar toplines small Phase 2a dataset in autoimmune liver disease

2 months ago

Cassava ends work on Alzheimer's drug; Alumis gets $40M upfront from Kaken

2 months ago

Ophthalmology startup Character Biosciences gets $93M for genetics-based approach

2 months ago

First page Previous page 24 25 262728 29 30 Next page Last page